AUTHORS
Julia Castro Weiss, Veronika Pokorna, MD2, Naseema Gangat, MBBS3, Nickolas Steinauer, M.D., Ph.D.4, Abhishek Avinash Mangaonkar, MBBS5, Aref Al-Kali, M.D.6, Tariq Kewan, MD7, Antoine N. Saliba, M.D.8, Kaaren Reichard, MD9, Terra Lasho, PhD10, Christy Finke, BS11, Hassan B Alkhateeb, M.D.12, William Hogan, M.B., B.Ch.13, Jenna Fernandez, Ph.D.14, Mithun Shah, MD, PhD15, Mrinal M. Patnaik, MD, MBBS16
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Charles University in Prague, Faculty of Medicine Hradec Kralove, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic, Mayo Clinic, Rochester, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Chronic myelomonocytic leukemia (CMML) is a clonal myeloid neoplasm characterized by sustained monocytosis. Cutaneous manifestations occur in up to 30% of patients with CMML and include clonal myeloid infiltrates and inflammatory dermatoses. We assembled a molecularly annotated cohort to characterize cutaneous features and clinical outcomes.
Methods: After IRB approval, we retrospectively reviewed 401 patients with CMML to identify biopsy-confirmed cutaneous manifestations. Skin biopsies were classified into predefined diagnostic categories (12 mutually exclusive categories), with clonal myeloid infiltrates (Category 1) and CMML-associated inflammatory dermatoses (Category 2) considered disease-related. Clinical, molecular (38-gene panel), and outcome analyses were performed at the patient level. Standard statistical measures were applied.
Results: A total of 459 biopsies were available from 127 patients (median 3 biopsies per patient, IQR 1-4); median age 73 years (range, 30.6–91.8), 66.9% males (85/127). Most frequently represented cutaneous categories were skin cancers, including premalignant lesions (36.4%; 167/459), benign cutaneous lesions (20.0%; 92/459), CMML-associated inflammatory dermatoses (Category 2: 10.0%; 46/459), clonal myeloid involvement (Category 1: 7.8%; 36/459), non-CMML-associated inflammatory dermatoses (7.6%; 35/459), infectious lesions (3.3%; 15/459), reactive/nonspecific changes (1.1%; 5/459), and other findings (3.7%; 17/459). GVHD and drug-related manifestations (11.9% ;55/459) were excluded from analysis.
Overall, CMML-associated cutaneous manifestations were identified in 17.9% of biopsies (82/459), representing 35.4% of patients in the skin-biopsy cohort and 11.2% of all patients. Category 1 and 2 manifestations occurred in 15.0% (19/127) and 22.8% (29/127) of biopsied patients, with 2.4% (3/127) demonstrating both phenotypes.
Cutaneous clonal involvement included mature myelomonocytic infiltrates without blasts or blast equivalents (42.1%, 8/19), mature plasmacytoid dendritic-cell infiltrates and blastic plasmacytoid dendritic-cell infiltrates (each 10.5%, 2/19), histiocytic infiltrates, mast-cell infiltrates, and myeloid sarcoma (each 10.5%, 2/19), and cutaneous involvement by acute myeloid leukemia (AML;15.8%, 3/19). CMML-associated inflammatory dermatoses included vasculitis (34.5%, 10/29), Sweet syndrome (27.6%, 8/29), Grover disease (10.3%, 3/29), erythema nodosum and panniculitis (each 6.9%, 2/29), and less frequent inflammatory phenotypes.
Somatic mutational burdens did not differ significantly by CMML-related cutaneous manifestation status (p=0.505). Among patients with nonoverlapping CMML-related cutaneous phenotypes, neither total mutation burden (p=0.210) nor the prevalence of multiple mutations (p=0.688) differed significantly between Category 1 and 2. No individual mutation was significantly associated with Category 1, with NRAS demonstrating a nonsignificant enrichment (9.8% vs 3.8%;OR 2.73; P=0.053), as did the combined RAS-pathway group (7.3% vs 3.2%;OR 2.37; P=0.09). In contrast, Category 2 inflammatory dermatoses were independently associated with lower ASXL1 (adj. OR 0.17, 95% CI 0.06–0.501; P=0.001) and higher TP53 mutation frequency (adj. OR 6.88, 95% CI 2.02–23.40; P=0.002). Overall mutation burden did not differ between phenotypes. Histologically, Category 1 lesions comprised lineage-defined monocytic/myelomonocytic, histiocytic, plasmacytoid dendritic-cell, mast-cell, and blastic infiltrates, whereas Category 2 lesions were predominantly vasculitic and neutrophilic inflammatory dermatoses.
Category 1 cutaneous involvement was associated with AML transformation (42.1% vs 16.8%; OR 3.60, 95% CI 1.21–10.27; P=0.01). However, in 5 of 8 patients (62.5%) who developed AML, the first Category 1 manifestation documented on or after AML transformation, suggesting that cutaneous involvement more often reflects advanced disease than predicts leukemic progression. Category 2 inflammatory dermatoses were not associated with AML transformation (10.3% vs 18.5%; OR 0.51; P=0.33).
Conclusion: This study demonstrates that CMML-associated clonal and inflammatory cutaneous manifestations are biologically distinct entities with divergent molecular associations and clinical behavior. Inflammatory dermatoses were associated with specific genomic alterations rather than increased mutational complexity, whereas clonal cutaneous involvement primarily reflected advanced disease.
DISCLOSURES
Julia Castro Weiss: No relevant conflicts of interest to declare.